[{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"AB-729","moa":"Viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antios Therapeutics \/ Antios Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Antios Therapeutics"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Assembly Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"ATI-2173","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antios Therapeutics \/ Antios Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Antios Therapeutics \/ Antios Therapeutics"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"GordonMD Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"AB-729","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ GordonMD Global Investments","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ GordonMD Global Investments"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"IRBM","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Capsid assembly","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antios Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Antios Therapeutics \/ Antios Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Antios Therapeutics \/ Antios Therapeutics"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clevudine Monophosphate Prp","moa":"Active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clevudine Monophosphate Prodrug","moa":"Nucleotide active site polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ATI-1428","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ATI-2173","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Antios Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.

                          Brand Name : ATI-2173

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2022

                          Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ATI-1428 and ATI-1645 are 4th generation, class II capsid assembly modulators (CAMs), both with a novel and unique ultra-potent mechanism of action design that may provide for a more targeted, productive antiviral response by the immune system.

                          Brand Name : ATI-1428

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 08, 2022

                          Lead Product(s) : ATI-1428

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.

                          Brand Name : ATI-2173

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 26, 2022

                          Lead Product(s) : Clevudine Monophosphate Prodrug,Tenofovir,Vebicorvir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.

                          Brand Name : ATI-2173

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 30, 2022

                          Lead Product(s) : Clevudine Monophosphate Prp,Tenofovir Disoproxil Fumarate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Antios will purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) which is being developed for the treatment of HBV.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 15, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : IRBM

                          Deal Size : $50.0 million

                          Deal Type : Acquisition

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds from this financing will be used to advance the clinical development of ATI-2173, Antios’ lead Phase 2b clinical candidate. ATI-2173 is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development.

                          Brand Name : ATI-2173

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 03, 2021

                          Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate,AB-729

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : GordonMD Global Investments

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.

                          Brand Name : ATI-2173

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 19, 2021

                          Lead Product(s) : ATI-2173,Vebicorvir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Recipient : Assembly Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The multi-center, double-blinded, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of the combination of ATI-2173, AB-729 and Viread.

                          Brand Name : GalNAc-RNAi

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 30, 2021

                          Lead Product(s) : AB-729,ATI-2173,Tenofovir Disoproxil Fumarate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Arbutus Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The double-blind randomized controlled trial plans to enroll 30 patients and will assess the safety and efficacy of 25mg and 50mg doses of ATI-2173 in combination with tenofovir (TDF) compared with TDF plus ATI-placebo (control) in chronic HBV-infected s...

                          Brand Name : ATI-2173

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 21, 2021

                          Lead Product(s) : ATI-2173

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, ATI-2173, to be a backbone of a once-daily curative regimen for chronic hepatitis B.

                          Brand Name : ATI-2173

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2021

                          Lead Product(s) : ATI-2173

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : RA Capital Management

                          Deal Size : $96.0 million

                          Deal Type : Series B Financing

                          blank